Contact

All Stories

  1. A multi-strain probiotic modulates gut microbiome composition, intestinal barrier integrity and inflammation in a multi-compartmental in vitro gut model of decompensated alcohol-related advanced chronic liver disease

    Article • International Journal of Pharmaceutics, February 2026, Elsevier

    Dr Vishal C Patel

  2. Enhancing infection diagnostics in advanced chronic liver disease: harnessing clinical metagenomics for rapid pathogen and antimicrobial resistance detection

    Article • npj Antimicrobials and Resistance, January 2026, Springer Science + Business Media

    Dr Vishal C Patel

  3. Microbial collagenase activity is linked to oral–gut translocation in advanced chronic liver disease

    Article • Nature Microbiology, December 2025, Springer Science + Business Media

    Dr Vishal C Patel

  4. Decoding the microbiome and resistome of advanced chronic liver disease through long-read metagenomics

    Article • December 2025, openRxiv

    Dr Vishal C Patel

  5. Gene-centric metagenomic analyses reveal microbiome functional insights into diseases

    Article • September 2025, openRxiv

    Dr Vishal C Patel

  6. Plasmin-mediated proteolysis of von Willebrand factor in patients with acute and chronic liver disease

    Article • Research and Practice in Thrombosis and Haemostasis, August 2025, Elsevier

    Dr Vishal C Patel

  7. FMT for hepatic encephalopathy? The THEMATIC trial aims to make it a ‘no brainer’

    Article • Journal of Hepatology, July 2025, Elsevier

    Dr Vishal C Patel

  8. Pediatric Liver and Kidney Transplant Recipients Demonstrate Greater Serological Response to SARS-CoV-2 Vaccination Than Adults

    Article • Transplantation Direct, April 2025, Wolters Kluwer Health

    Dr Antonio Riva, Dr Vishal C Patel

  9. Lipidomics-based Plasma Signature of Alcohol-Related Hepatitis Linked to Short-Term Mortality

    Article • JHEP Reports, March 2025, Elsevier

    Dr Vishal C Patel

  10. Enhanced Computational and Experimental Approaches for Comparative Analysis of the Human Mycobiome

    Article • February 2025, openRxiv

    Dr Vishal C Patel

  11. Decompensated Liver Cirrhosis Research Network (UK-CLIF): Building consensus for hepatology trials in the UK

    Article • NIHR Open Research, November 2024, National Institute for Health Research

    Dr Vishal C Patel

  12. microRNA associated with hepatocyte injury and systemic inflammation may predict adverse outcomes in cirrhotic patients

    Article • Scientific Reports, October 2024, Springer Science + Business Media

    Dr Vishal C Patel

  13. Oral-gut microbiome interactions in advanced cirrhosis: characterisation of pathogenic enterotypes and salivatypes, virulence factors and antimicrobial resistance

    Article • Journal of Hepatology, October 2024, Elsevier

    Dr Vishal C Patel

  14. Limitations of current techniques in clinical antimicrobial resistance diagnosis: examples and future prospects

    Article • npj Antimicrobials and Resistance, June 2024, Springer Science + Business Media

    Dr Vishal C Patel

  15. OS-070 Faecal microbiota transplantation in patients with cirrhosis, reduces antimicrobial resistance and enteric pathogen carriage, and enhances intestinal barrier function, associated with bacteriophage remodelling

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish, Dr Vishal C Patel

  16. THU-317 Alcohol-related hepatitis is associated with a distinctive pattern of disordered bile acid metabolism and reduced bile acid transporter expression

    Article • Journal of Hepatology, June 2024, Elsevier

    Dr Benjamin Mullish, Dr Vishal C Patel

  17. Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: study protocol for a randomised controlled trial

    Article • Trials, April 2024, Springer Science + Business Media

    Dr Vishal C Patel

  18. Beta-blockers or Placebo for Primary Prophylaxis (BOPPP) of oesophageal varices: Study protocol for a randomised controlled trial

    Article • December 2023, Cold Spring Harbor Laboratory Press

    Dr Vishal C Patel

  19. Von Willebrand factor as a predictor of mortality in acute‐on‐chronic liver failure: Do not throw out the baby with the bathwater

    Article • Liver International, December 2023, Wiley

    Dr Vishal C Patel

  20. Serological response and breakthrough infection after COVID-19 vaccination in patients with cirrhosis and post-liver transplant

    Article • Hepatology Communications, October 2023, Wolters Kluwer Health

    Dr Vishal C Patel, Xavier Verhelst, Dr Antonio Riva

  21. Fibrin clots from patients with acute-on-chronic liver failure are weaker than those from healthy individuals and patients with sepsis without underlying liver disease

    Article • Journal of Thrombosis and Haemostasis, October 2023, Elsevier

    Dr Vishal C Patel

  22. Von Willebrand factor is an independent predictor of short‐term mortality in acutely ill patients with cirrhosis

    Article • Liver International, September 2023, Wiley

    Dr Vishal C Patel

  23. Pathogenic entero- and salivatypes harbour changes in microbiome virulence and antimicrobial resistance genes with increasing chronic liver disease severity

    Article • August 2023, Cold Spring Harbor Laboratory Press

    Dr Vishal C Patel

  24. In vivo generation of thrombin in patients with liver disease without apparent evidence of activation of the intrinsic or extrinsic pathway of coagulation

    Article • Journal of Thrombosis and Haemostasis, August 2023, Elsevier

    Dr Vishal C Patel

  25. Impact of liver failure on the circulating extracellular vesicle miRNA repertoire

    Article • Hepatology Research, May 2023, Wiley

    Dr Vishal C Patel

  26. Lysophosphatidylcholines modulate immunoregulatory checkpoints in peripheral monocytes and are associated with mortality in people with acute liver failure

    Article • Journal of Hepatology, March 2023, Elsevier

    Dr Vishal C Patel

  27. AXL Expression on Homeostatic Resident Liver Macrophages Is Reduced in Cirrhosis Following GAS6 Production by Hepatic Stellate Cells

    Article • Cellular and Molecular Gastroenterology and Hepatology, January 2023, Elsevier

    Dr Vishal C Patel

  28. Carvedilol in patients with compensated cirrhosis: the ongoing benefits of definitive randomised trials over meta-analysis in patients with small varices

    Article • Journal of Hepatology, December 2022, Elsevier

    Dr Vishal C Patel

  29. General practitioner perspectives on factors that influence implementation of secondary care-initiated treatment in primary care: Exploring implementation beyond the context of a clinical trial

    Article • PLOS One, October 2022, PLOS

    Dr Vishal C Patel

  30. P26 Circulating markers of neutrophil extracellular traps are associated with excessive coagulation activation in decompensated cirrhosis and acute-on-chronic liver failure

    Article • September 2022, BMJ

    Dr Vishal C Patel

  31. P25 Rapid Infection Diagnostics in Cirrhosis (RIDiC): a novel molecular-based approach to address the ever increasing challenge of antimicrobial resistant infections in decompensated cirrhosis and acute-on-chronic liver failure

    Article • September 2022, BMJ

    Dr Vishal C Patel

  32. P39 Systemic inflammation associated microRNA as novel biomarkers for clinical decompensation in patients with cirrhosis

    Article • September 2022, BMJ

    Dr Vishal C Patel

  33. Images of the month 1: Histoacryl glue embolisation to the right ventricle following treatment for gastric varices

    Article • Clinical Medicine, March 2022, Elsevier

    Dr Vishal C Patel

  34. Using a theory-informed approach to explore patient and staff perspectives on factors that influence clinical trial recruitment for patients with cirrhosis and small oesophageal varices

    Article • PLOS One, February 2022, PLOS

    Dr Vishal C Patel

  35. Fibrin clot quality in acutely ill cirrhosis patients: Relation with outcome and improvement with coagulation factor concentrates

    Article • Liver International, December 2021, Wiley

    Dr Vishal C Patel

  36. IL-1 Signal Inhibition In Alcoholic Hepatitis (ISAIAH): a study protocol for a multicentre, randomised, placebo-controlled trial to explore the potential benefits of canakinumab in the treatment of alcoholic hepatitis

    Article • Trials, November 2021, Springer Science + Business Media

    Dr Vishal C Patel

  37. Prevalence of Bleeding and Thrombosis in Critically Ill Patients with Chronic Liver Disease

    Article • Thrombosis and Haemostasis, October 2021, Thieme Publishing Group

    Dr Vishal C Patel

  38. Aberrant hepatic trafficking of gut‐derived T‐cells is not specific to primary sclerosing cholangitis

    Article • Hepatology, October 2021, Wiley

    Dr Vishal C Patel

  39. Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial

    Article • Journal of Hepatology, September 2021, Elsevier

    Dr Vishal C Patel

  40. Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19

    Article • JAMA, July 2021, American Medical Association (AMA)

    Dr Vishal C Patel

  41. The Lipopolysaccharide-Sensing Caspase(s)-4/11 Are Activated in Cirrhosis and Are Causally Associated With Progression to Multi-Organ Injury

    Article • Frontiers in Cell and Developmental Biology, July 2021, Frontiers

    Dr Vishal C Patel

  42. Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute‐on‐Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid–Dependent Monocyte Activation

    Article • Hepatology, June 2021, Wiley

    Dr Vishal C Patel

  43. Hemostatic balance in acute‐on‐chronic liver failure

    Article • Journal of Thrombosis and Haemostasis, March 2021, Wiley

    Dr Vishal C Patel

  44. P225 Partial splenic artery embolisation for portal hypertension – a single centre experience

    Article • January 2021, BMJ

    Dr Vishal C Patel

  45. Global hemostatic status in patients with acute‐on‐chronic liver failure and septics without underlying liver disease

    Article • Journal of Thrombosis and Haemostasis, November 2020, Wiley

    Dr Vishal C Patel

  46. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology

    Article • Journal of Hepatology, October 2020, Elsevier

    Clinical Chair Professor Henning Gronbaek, Dr Maurizio Baldassarre, Dr Vishal C Patel

  47. Modulating the gut–liver axis and the pivotal role of the faecal microbiome in cirrhosis

    Article • Clinical Medicine, September 2020, Royal College of Physicians

    Dr Vishal C Patel

  48. Results of the PROFIT trial, a PROspective randomised placebo-controlled feasibility trial of Faecal mIcrobiota Transplantation in advanced cirrhosis

    Article • Journal of Hepatology, August 2020, Elsevier

    Dr Benjamin Mullish, Dr Vishal C Patel

  49. Faecal cytokine profiling as a marker of intestinal inflammation in acutely decompensated cirrhosis

    Article • JHEP Reports, July 2020, Elsevier

    Dr Vishal C Patel, Dr Antonio Riva

  50. Whole blood thrombin generation profiles of patients with cirrhosis explored with a near patient assay

    Article • Journal of Thrombosis and Haemostasis, February 2020, Wiley

    Dr Vishal C Patel

  51. Antimicrobial resistance in chronic liver disease

    Article • Hepatology International, December 2019, Springer Science + Business Media

    Dr Vishal C Patel

  52. Mixed Fibrinolytic Phenotypes in Decompensated Cirrhosis and Acute‐on‐Chronic Liver Failure with Hypofibrinolysis in Those With Complications and Poor Survival

    Article • Hepatology, October 2019, Wiley

    Dr Vishal C Patel

  53. P: 71 Faecal Cytokine Profiling Provides Novel Insights Into Intestinal Barrier Disruption and Bacterial Translocation in Acute Decompensation of Cirrhosis

    Article • The American Journal of Gastroenterology, September 2019, Wolters Kluwer Health

    Dr Vishal C Patel

  54. P: 12 PROFIT: PROspective, Randomised Placebo-controlled Feasibility Trial of Faecal Microbiota Transplantation in Cirrhosis Interim Analysis

    Article • The American Journal of Gastroenterology, September 2019, Wolters Kluwer Health

    Dr Vishal C Patel

  55. P: 38 Rifaximin Reduces the Incidence of Spontaneous Bacterial Peritonitis, Variceal Bleeding and All-cause Admissions in Patients on the Liver Transplant Waiting List

    Article • The American Journal of Gastroenterology, September 2019, Wolters Kluwer Health

    Dr Vishal C Patel

  56. Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list

    Article • Alimentary Pharmacology & Therapeutics, June 2019, Wiley

    Dr Vishal C Patel

  57. PS-174-Serum bile acid profiles distinguish severe alcoholic hepatitis from decompensated alcohol-related cirrhosis

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Benjamin Mullish, Dr Vishal C Patel

  58. PS-144-Autotaxin mediates lipid dysregulation in acute-on-chronic liver failure, promoting persistence of systemic inflammation via lysophosphatidic acid-mediated monocyte activation

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Vishal C Patel

  59. THU-052-Immunometabolic profiling of ascites from patients with acute-on-chronic liver failure reveals increased MerTK+ immunosuppressive myeloid cells and cell death markers with preferential lipid metabolism compared to cirrhosis without organ failure

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Vishal C Patel

  60. THU-055-Improved stratification of liver failure syndromes using broad-panel bile acid LCMS phenotyping demonstrates novel pathways of dysregulation in tertiary bile acids in acute-on-chronic liver failure

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Vishal C Patel

  61. FRI-099-PD-1+ monocytes and macrophages contribute to impaired microbial clearance following acute liver failure

    Article • Journal of Hepatology, April 2019, Elsevier

    Dr Vishal C Patel

  62. PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial

    Article • BMJ Open, February 2019, BMJ

    Dr Vishal C Patel

  63. Therapeutic plasma exchange as a novel treatment for severe intrahepatic cholestasis of pregnancy: Case series and mechanism of action

    Article • Journal of Clinical Apheresis, October 2018, Wiley

    Dr Vishal C Patel

  64. PTH-106 Plasma S100A8/A9: a novel mechanistic biomarker in innate immune activation in acute-on-chronic liver failure

    Article • June 2018, BMJ

    Dr Vishal C Patel

  65. In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis

    Article • Liver International, May 2018, Wiley

    Dr Vishal C Patel

  66. Results of a placebo-controlled double blind randomised trial to investigate the efficacy of rifaximin-alpha versus placebo in improving systemic inflammation in patients with cirrhosis and chronic hepatic encephalopathy (RIFSYS Trial)

    Article • Journal of Hepatology, April 2018, Elsevier

    Dr Vishal C Patel

  67. Platelet-leucocyte aggregation is augmented in cirrhosis and further increased by platelet transfusion

    Article • Alimentary Pharmacology & Therapeutics, March 2018, Wiley

    Dr Vishal C Patel

  68. Balanced haemostasis with both hypo- and hyper-coagulable features in critically ill patients with acute-on-chronic-liver failure

    Article • Journal of Critical Care, February 2018, Elsevier

    Dr Vishal C Patel

  69. Mucosa-associated invariant T cells link intestinal immunity with antibacterial immune defects in alcoholic liver disease

    Article • Gut, November 2017, BMJ

    Dr Antonio Riva, Dr Vishal C Patel

  70. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease

    Article • Alimentary Pharmacology & Therapeutics, October 2017, Wiley

    Dr Vishal C Patel

  71. CD14+CD15−HLA-DR−myeloid-derived suppressor cells impair antimicrobial responses in patients with acute-on-chronic liver failure

    Article • Gut, June 2017, BMJ

    Dr Vishal C Patel

  72. MerTK expressing hepatic macrophages promote the resolution of inflammation in acute liver failure

    Article • Gut, April 2017, BMJ

    Dr Vishal C Patel

  73. High-Speed Quantitative UPLC-MS Analysis of Multiple Amines in Human Plasma and Serum via Precolumn Derivatization with 6-Aminoquinolyl-N-hydroxysuccinimidyl Carbamate: Application to Acetaminophen-Induced Liver Failure

    Article • Analytical Chemistry, February 2017, American Chemical Society (ACS)

    Dr Vishal C Patel

  74. MAIT cell dysfunctions correlate with markers of intestinal integrity in ALD patients

    Article • Journal of Hepatology, January 2017, Elsevier

    Dr Vishal C Patel

  75. Multivariate metabotyping of plasma predicts survival in patients with decompensated cirrhosis

    Article • Journal of Hepatology, May 2016, Elsevier

    Dr Vishal C Patel

  76. The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin-α

    Article • Liver International, April 2016, Wiley

    Dr Vishal C Patel

  77. Neutrophil Toll-Like Receptor 9 Expression and the Systemic Inflammatory Response in Acetaminophen-Induced Acute Liver Failure

    Article • Critical Care Medicine, January 2016, Wolters Kluwer Health

    Dr Antonio Riva, Dr Vishal C Patel

  78. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial

    Article • Journal of Hepatology, January 2016, Elsevier

    Dr Vishal C Patel

  79. Altered Gut Microbial Profile is a Proponent of Bacterial Translocation in Acute-on-Chronic Liver Failure

    Article • Journal of Hepatology, January 2016, Elsevier

    Dr Vishal C Patel

  80. Dramatic Alterations of Anti-Bacterial Mait-Cell Network in Alcoholic Liver Disease

    Article • Journal of Hepatology, January 2016, Elsevier

    Dr Vishal C Patel

  81. Mer Tyrosine Kinase Regulates the Activation of Myeloid Cells and Innate Immune Responses in Acute-on-Chronic Liver Failure

    Article • Journal of Hepatology, January 2016, Elsevier

    Dr Vishal C Patel

  82. The Formation of Activated Platelet-Complexed Leukocytes is Augmented in Cirrhosis and Enhanced by Platelet Transfusion

    Article • Journal of Hepatology, January 2016, Elsevier

    Dr Vishal C Patel

  83. Clinical science workshop: targeting the gut-liver-brain axis

    Article • Metabolic Brain Disease, October 2015, Springer Science + Business Media

    Dr Vishal C Patel

  84. Bile Acid Profiling and Quantification in Biofluids Using Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry

    Article • Analytical Chemistry, September 2015, American Chemical Society (ACS)

    Dr Vishal C Patel

  85. Increased Survival for Patients With Cirrhosis and Organ Failure in Liver Intensive Care and Validation of the Chronic Liver Failure–Sequential Organ Failure Scoring System

    Article • Clinical Gastroenterology and Hepatology, July 2015, Elsevier

    Dr Maheeba Abdulla, Dr Vishal C Patel

  86. Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure

    Article • Immunotherapy, July 2015, Future Medicine

    Dr Vishal C Patel

  87. Salivary microbiota-immune profiling in cirrhosis: Could this be the noninvasive strategy that will revolutionize prognostication in hepatology?

    Article • Hepatology, June 2015, Wiley

    Dr Vishal C Patel

  88. P1329 : A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin in improving systemic inflammation and neutrophil malfunction in patients with cirrhosis and chronic hepatic encephalopathy (‘RIFSYS’)

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Vishal C Patel

  89. P1119 : Elevated levels of circulating bacterial DNA in alcoholic hepatitis identifies patients who will not respond to corticosteroid

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Vishal C Patel

  90. P1294 : Proof-of-principle evaluation of immunomodulatory drugs in promoting phagocytosis capacity in patients with liver failure

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Vishal C Patel

  91. P0168 : The impact on hospital resource utilisation of Rifaximin-alpha for hepatic encephalopathy in routine clinical practice: Real world data from seven UK liver centres

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Vishal C Patel

  92. O106 : Therapeutic plasma exchange modulates innate immune activation and improves outcome in patients with acute liver failure

    Article • Journal of Hepatology, April 2015, Elsevier

    Dr Vishal C Patel

  93. Patients With Acute-on-Chronic Liver Failure Have Increased Numbers of Regulatory Immune Cells Expressing the Receptor Tyrosine Kinase MERTK

    Article • Gastroenterology, March 2015, Elsevier

    Dr Vishal C Patel

  94. OC-029 Rifaximin Is Efficacious In The Treatment Of Chronic Overt Hepatic Encephalopathy: A Uk Liver Multi-centre Experience

    Article • Gut, June 2014, BMJ

    Dr Vishal C Patel

  95. P314 CHARACTERISATION OF THE PLASMA METABOLIC PHENOTYPE OF ACUTE LIVER FAILURE BY H NMR SPECTROSCOPY

    Article • Journal of Hepatology, April 2014, Elsevier

    Dr Vishal C Patel

  96. P164 MONOCYTE EXHAUSTION: A MECHANISTIC EXPLANATION FOR SUSCEPTIBILITY TO INFECTION IN LIVER FAILURE

    Article • Journal of Hepatology, April 2014, Elsevier

    Dr Vishal C Patel

  97. Diabetes and the gastrointestinal tract

    Article • Medicine, May 2011, Elsevier

    Dr Vishal C Patel

  98. Retrospective analysis of the impact of a low glycaemic index diet on hospital stay following coronary artery bypass grafting: a hypothesis

    Article • Journal of Human Nutrition and Dietetics, June 2004, Wiley

    Dr Vishal C Patel